Neurocrine Biosciences (NASDAQ:NBIX) reported quarterly earnings of $1.24 per share which beat the analyst consensus estimate of $1.14 by 8.77 percent. This is a 3000 percent increase over earnings of $0.04 per share from the same period last year. The company reported quarterly sales of $412.00 million which beat the analyst consensus estimate of $409.09 million by 0.71 percent. This is a 32.05 percent increase over sales of $312.00 million the same period last year.
B of A Securities Maintains Neutral on Autodesk, Raises Price Target to $240
B of A Securities analyst Michael Funk maintains Autodesk (NASDAQ:ADSK) with a Neutral and raises the price target from $225 to $240.
